, using antibodies isolated from patients with autoimmune syndromes of insulin resistance to immunoprecipitate the receptor, demonstrated that it becomes phosphorylated on tyrosine residues in response to insulin binding -an unexpected finding, as tyrosine phosphorylation had until then been thought of as exclusive to oncogenes. Not until the insulin receptor (IR) cDNA was cloned by the Ullrich and Rutter groups in 1985 (REFS 5, 6) did the notion of tyrosine phosphorylation as the basis for insulin signalling become widely adopted, effectively shifting attention from the cell surface to the intracellular pathways mediating the diverse actions of the receptor (FIG. 1) .
In 1991, White and Kahn 7 cloned the first of four IR substrate (IRS) proteins, a family of adaptor proteins whose main role is to convert the tyro sine phosphorylation signal into a lipid kinase signal by recruiting the catalytic subunit of the enzyme PI3K. The latter generates the triphosphorylated inositol required to activate the serine/threonine kinase AKT. The identification of AKT 8 as an insulin-activated serine/threonine kinase solved the riddle of how the tyrosine phosphorylation signal is converted into a serine/threonine phosphorylation signal. In fact, while it had long been apparent that most actions of insulin required the phosphorylation of serine/ threonine residues on various substrates, efforts to demonstrate direct effects of insulin on serine/ threonine kinases had fallen short. AKT provided the missing link that enabled the clarification of the distal steps in insulin signalling, such as the modulation of glucose uptake by glucose transporter type 4 (GLUT4), glycogen synthesis by glycogen synthase kinase 3 (GSK3), protein and fat synthesis by mTOR and gene expression by forkhead family box O (FOXO) (FIG. 2) . Insulin has complex effects on metabolism, cell growth and differentiation. Virtually all mammalian cells possess IRs and hence respond to insulin. The major tissues targeted by insulin's effects on metabolism include: muscle, where insulin promotes glucose uptake and protein synthesis; adipose tissue, where insulin promotes glucose and fatty acid uptake and inhibits lipolysis; the liver, where insulin promotes glucose utiliza tion, suppresses glucose production, and promotes triglyceride synthesis; and neurons, where it promotes anorexigenic and locomotor signals. Additional notable insulin target cells with a metabolic function include macrophages, endothelial cells and insulin-producing pancreatic β-cells. Moreover, some of the key medi ators of insulin signalling -PI3K and AKT -are activ ated downstream of other growth factor receptors, and conversely some mitogenic pathways -growth factor receptorbound protein 2 (GRB2) and ERK 9 -are activated by insulin, creating a network of interacting signalling pathways 10 . Therefore, insulin's signalling mechanisms are complex, and this historical overview falls necessarily short of crediting additional signalling pathways that contribute to the hormone's diverse effects. Nonetheless, human genetics, animal models and cellular biology have built a consensus around the pathways described above as the main signalling nodes.
In this Review, we focus mainly on the cellular mechanisms of insulin signalling and on new insights into pathways of primary relevance to insulin's metabolic effects. We describe newly discovered elements of IR signal transduction and how they relate to the main meta bolic actions of insulin. We focus on how the IR signal is modulated, including antagonistic proteins and combinator ial interactions among different isoforms, as well as temporal and spatial regulation of cellular insulin signalling. We also highlight key aspects of how these pathways fit into physiology and the pathophysiology of type 2 diabetes, with the general theme that increased insulin action is associated with increased insulin sensitiv ity, as defined by a leftward shift in the dose-response curve for insulin action on glucose levels. However, work in this field has also identified multiple examples of insulin sensitivity being uncoupled from IR activity [11] [12] [13] [14] [15] and other suggestions that insulin resistance is an adaptive trait 16, 17 . For recent reviews on insulin resistance, we refer the reader to Antagonistic signalling Every step in the insulin signalling cascade is a reversible enzymatic reaction. Thus, for each kinase activated by insulin, there are (often multiple) phosphatases that termin ate its action. Moreover, in addition to the vast reper toire of serine/threonine kinases regulated by insulin, there is an even larger group of phosphatases that actively suppress the actions of the insulin-activated kinases. Furthermore, different post-translational modifi cations of the same target protein often result in different bio logical effects. These mechanisms are as important as signalling initiation but, because of their redundancy, have proved less amenable to cellular and genetic analyses. An overview of antagonistic signalling mechanisms is shown in FIG. 3a .
Insulin. The hormone itself is arguably the most important negative regulator of its own signalling. Similar to other receptor tyrosine kinases, IR undergoes ligandinduced internalization and lysosomal degradation or recycling back to the cell surface 21 (FIG. 3b) . This event requires a 12-amino-acid motif located on the intracellular part of the IR juxtamembrane domain 22 . This motif targets the receptor to clathrin-coated pits, and from there to lysosomes, whose acidic pH is thought to favour insulin release. Thus, as insulin levels rise, receptor downregulation at the cell surface paradoxically decreases insulin signalling, contributing to its termin ation. This is the basis of the common observation that insulin resistance is associated with hyperinsulinaemia. However, because this phenomenon is strictly depen dent on plasma insulin concentrations, it is promptly reversed when insulin levels fall, most notably after fasting in humans 23 .
Inhibitory phosphorylation. As a general rule, tyrosine phosphorylation activates, and serine/threonine phosphorylation inactivates, IR and IRS proteins 18, 24 . At a more granular level, the effects are site-dependent, but serine/threonine phosphorylation is a major mechanism by which IR signalling is fine-tuned, antagonized or terminated.
One example that has been well-studied in vitro is the serine/threonine phosphorylation of IRS by the mTOR-ribosomal protein S6 kinase (S6K) pathway, which may link prolonged insulin signalling with decreased IRS protein levels. Unrestrained activation of S6K causes serine/threonine phosphorylation of IRS, which results in decreased IRS signalling and proteasomal degradation 25, 26 (FIG. 3c) . Additional work has shown that mTOR and S6K phosphorylate IRS at multiple residues 24 . Consistent with this concept, knocking out S6K1 from mice reduces weight gain and enhances insulin sensitivity 27 . However, the importance of IRS serine/ threonine phosphorylation in these phenotypes and in insulin action in general has been called into question.
Mice with a knock-in allele of IRS1 in which the reported S6K-directed phosphorylation site (Ser302) was mutated to alanine showed no alterations in insulin action 28 . Thus, the mechanisms linking mTOR-S6K signalling to impaired insulin action may be independent of IRS. Nature Reviews | Molecular Cell Biology   1921  1950  1971  1982  1985  1989  1991  1993  1995  1998  1999  2003  2006  2010  2013   Discovery  of insulin   1   Demonstration  of the  existence of a  membrane  receptor for  insulin   3 Cloning of the insulin receptor cDNA 5, 6 Discovery 187, 188 Demonstration that FOXO mediates the interaction of insulin and leptin in CNS 245 Dynamic maps of insulin signalling determined by unbiased mass spectrometry 153, 154 Cloning of glucose transporters 241, 242 Figure 1 | Timeline of the major discoveries in insulin signalling. CNS, central nervous system; FOXO, forkhead family box O; TBC1D4, TBC1 domain family member 4.
Paracrine
A mechanism by which neighbouring cells influence each other by way of a secreted factor.
Diacylglycerol
A glycerol molecule with two fatty acid chains present in food or produced primarily in the liver, adipose tissue and intestine, diacylglycerol is best known for its signalling properties to activate protein kinase C but also functions as a precursor molecule in the synthesis of triglycerides and prostaglandins.
Haploinsufficiency
A phenotype caused by a heterozygous loss-of-function mutation, or by a mutation partly affecting levels and/or activity of a gene product.
A second pathway leading to inhibitory phosphorylation is initiated by inflammatory cytokines 29 . This pathway can be triggered by macrophage infiltration in adipose tissue during obesity 30, 31 . These macrophages secrete pro-inflammatory cytokines, including TNFα, IL-1β, and IL-6, which act in a paracrine manner to activ ate serine kinases in adipocytes, including IκB kinase β (IKKβ), c-Jun N-terminal kinase (JNK), S6K and mTOR 32 (FIG. 3) . These kinases carry out inhibitory phosphorylation of IRS1, thus causing insulin resistance in adipocytes. Consistent with this, activation of inflammatory pathways can impair glucose metabolism and cause systemic insulin resistance 32, 33 . Recent evidence demonstrates that immune cell activation in liver, muscle, pancreas and brain can also impair local insulin signalling and lead to metabolic dysfunction 32 . However, the physiological relevance of IRS serine/threonine phosphorylation in these tissues has been questioned. Mice carrying an IRS1 allele in which the expected TNFα-dependent phosphorylation site (Ser307) is mutated to alanine showed impaired insulin action 34 , the opposite of what would have been expected based on the paradigm established in vitro. This underscores our incomplete understanding of these pathways and the involvement of IRS serine/threonine phosphorylation in insulin action in vivo.
A third mechanism of IR antagonism is caused by lipotoxicity (FIG. 3) . Diacylglycerol-dependent activation of protein kinase Cε (PKCε) impairs IR autophosphoryl ation by phosphorylating Thr1160 in the activation loop of IR 35 . Indeed, mutant mice in which this phosphorylation site has been mutated are protected against diet-induced impairment of insulin action in liver 35 but not in muscle, where the effects of diacylglycerol may instead be mediated by PKCθ 36 . In addition to diacylglycerol 36, 37 , ceramide accumulation can also impair AKT function by stimulating the activity of PKCζ, which alters membrane localization of AKT, and protein phosphatase 2A (PP2A) 38, 39 , which is described in more detail below.
Lipid phosphatases. The plasma membrane concentrations of the lipid second messenger PtdIns(3,4,5)P 3 are controlled not only at the level of synthesis by PI3K but also at the level of localization (see below) and degrad ation. Two lipid phosphatases are known to dephos phorylate PtdIns(3,4,5)P 3 and thereby attenuate downstream insulin signalling: PTEN and SHIP2 (Src homology 2 (SH2)-containing inositol 5ʹ-phosphatase 2) 40 (FIG. 3) .
PTEN is a 3ʹ-phosphatase that converts PtdIns (3,4,5)P 3 into its precursor, PtdIns(4,5)P 2 , and terminates insulin signalling (FIG. 3d) . This molecular function was uncovered in studies of DAF-18, the Caenorhabditis elegans homologue of PTEN 40, 41 . Moreover, PTEN has been long been recognized as a tumour suppressor that is frequently disrupted in human cancers 42, 43 . PTEN inhib ition increases AKT activity, thus amplifying not only the effects of insulin on glucose metabolism [44] [45] [46] [47] [48] [49] [50] but also cell growth and survival pathways 42 . PTEN haploinsufficiency in humans increases insulin sensitivity and results in weight gain 51 . Nature Reviews | Molecular Cell Biology SHIP2 is a 5ʹ-phosphatase that converts PtdIns(3,4,5)P 3 into PtdIns(3,4)P 2 . In vitro studies established that SHIP2 negatively regulates insulin-stimulated rat Akt phos phoryl ation 52 . Subsequent in vivo studies demonstrated that knockout of SHIP2 in mice protects against obesity and insulin resistance [53] [54] [55] . Likewise, glycaemia in rodent models of insulin resistance and diabetes has been shown to be improved by liver-specific expression of a dominant-negative form of SHIP2, SHIP knockdown (using antisense oligonucleotides against SHIP2), or a small-molecule SHIP2 inhibitor [56] [57] [58] [59] .
Protein phosphatases. The discovery of the tyrosine kinase activity of IR and IRS triggered a search for tyrosine phosphatases that terminate their activation. However, the nearly 100 members of this gene family do not have selective substrates but appear to be able to dephosphorylate tyrosine residues rather promiscuously; moreover, their activity appears to be constitutive, suggesting that IR and IRS tyrosine phosphorylation is transient. Specificity is probably achieved via subcellular localization and physical proximity. Protein tyrosine phosphatase 1B (PTP1B) negatively regulates insulin signalling by dephosphorylating tyrosine residues on IR and IRS proteins, and PTP1B ablation in mice is associ ated with increased insulin sensitivity [60] [61] [62] . This phosphatase appears to have a primary effect in the central nervous system [63] [64] [65] [66] , although increased IR and IRS phosphorylation in response to PTP1B depletion was shown in peripheral tissues as well [67] [68] [69] . PTP1B also negatively regulates leptin signalling, by acting on Janus kinase 2 (JAK2). Because the functions of leptin partly overlap with those of insulin, PTP1B (like FOXO1, see below) has the potential to be an integrative node in signal transduction underlying shared biological effects between the two hormones.
Pleckstrin homology domain and leucine-rich repeat protein phosphatase 1α (PHLPP1α), PHLPP1β, and PHLPP2 constitute a distinct family of serine/ threonine protein phosphatases 70, 71 (FIG. 3e). They were first discovered as AKT Ser473 phosphatases 72, 73 , but other substrates include PKC and S6K 74, 75 . PHLPP is involved in two separ ate negative feedback loops with insulin signalling. First, insulin signalling promotes PHLPP protein translation via mTOR-dependent activation of S6K and eukary otic translation initiation factor 4E-binding protein 1 (4EBP1) 76 . Second, insulin signalling stabilizes PHLPP protein. This occurs due to AKT phosphorylation and inhibition of GSK3β, which normally phosphorylates PHLPP, causing it to be degraded 77 
(FIG. 3e).
Protein phosphatase 2A (PP2A) is another serine/ threonine phosphatase that dephosphorylates Akt 78 . The holoenzyme comprises three subunits: structural, regulatory and catalytic. Because each has multiple isoforms, it has been estimated that 75 different holoenzymes are possible 79 . Certain components have been specifically linked with negative regulation of insulin signalling 80, 81 . However, in addition to AKT, there are numerous potential targets for PP2A-mediated dephosphorylation. This may underlie the paradoxical worsening of insulin resistance by PP2A inhibitors in mice 82 . Nature Reviews | Molecular Cell Biology Pseudosubstrates of the IR kinase. One set of IR signalling inhibitors are the adaptor proteins GRB10 and GRB14 (FIG. 3b) . These proteins contain two different domains that each bind to the IR (and the insulin-like growth factor 1 (IGF1) receptor) 83 . One is a unique peptide region referred to as BPS (between PH and SH2), which binds to the substrate-binding cleft of IR 84 . The second domain is an SH2 domain, which binds the phosphorylated tyrosine residues on IR 85 . Thus these GRBs act as pseudosubstrates and obstruct IRS binding and activation. Because the GRB SH2 domain protects IR phosphotyrosines from phosphatases, it potentiates IR phosphorylation, despite the overall function of these proteins as inhibitors [86] [87] [88] . It was recently revealed that GRB10 is part of a negative feedback loop, as it is an IR inhibitor that is stabilized downstream of IR. Using phospho proteomics, it was found that insulin signalling via Akt and mTOR complex 1 (mTORC1) causes direct phosphorylation of GRB10 (REFS 89, 90) . This stabilizes GRB10, thus perpetuating its inhibitory effect on IR (FIG. 3b) .
The physiological importance of these proteins is demonstrated by the improved insulin sensitivity seen in mice lacking GRB10, GRB14 or both 87, 88, 91, 92 . Human genetic studies also link these proteins with insulin signalling. Single nucleotide polymorphisms (SNPs) located within or near GRB10 correlate with glucose levels in the fasted state, glucose tolerance, glucose-stimulated insulin secretion and type 2 diabetes [93] [94] [95] [96] [97] . SNPs near GRB14 are associated with insulin levels, insulin sensitivity and type 2 diabetes 93,97-99 as well as adiposity, body fat distribution and body mass index 93, [100] [101] [102] [103] [104] [105] . A second set of IR inhibitory proteins are the SOCS proteins. Four members of this family (SOCS1, SOCS3, SOCS6 and SOCS7) have been shown to attenuate insulin signalling 106 . There are two mechanisms for this inhibition: one is that a SOCS protein -through its SH2 domain -binds and occupies the phospho tyrosine site of the IR (FIG. 3b) , and the second is that a SOCS protein -through its SOCS box domain -recruits a ubiquitin ligase to target IRS proteins for proteasomal degrad ation 106 (FIG. 3c) . Consistent with these molecular mech anisms, a body of evidence has suggested that reducing or inhibiting SOCS proteins would benefit insulin sensitiv ity in vivo 106 . Deleting SOCS3 specifically in muscle improves insulin signalling and insulinstimulated glucose disposal during feeding with a high-fat diet 107 . On the other hand, whole-body deletion of SOCS1 showed a trend towards improved glucose toler ance and was not protective against insulin resistance induced by a high-fat diet 108 . The latter studies carry the caveat that Socs1 −/− mice die within three weeks of birth, and these studies were therefore carried out in mice with a double knockout of Socs1 and a second gene, Rag2, which survive to adulthood 109 . On balance, most studies indicate a role for SOCS proteins in the termination of insulin signalling, and further investigation will clarify the pathophysiological effects of this pathway.
An interesting counterpoint to these inhibitory pseudosubstrates is provided by SH2B1, which instead enhances insulin signalling 83, 110 . This protein binds IR phosphotyrosine residues through its SH2 domain, thus protecting these IR residues from dephosphorylation. However, SH2B1 does not block the active site of the IR kinase, thus potentiating insulin signalling 83, 110 (FIG. 3) .
The role of this protein in insulin signalling in vivo has been confirmed by studies in flies and mice deficient in SH2B1, which demonstrate impaired glucose metabolism and blunted insulin signalling in muscle, liver and fat 111, 112 . Notably, the mouse studies were carried out in mice that lack SH2B1 in peripheral tissues but retain its expression in neurons, as this protein also impacts body weight by modulating leptin signalling 83, 110 . These pathways are validated by human genetic studies showing associations of SH2B1 polymorphisms with obesity and insulin resistance [113] [114] [115] [116] [117] [118] [119] [120] , although some findings indicate the gene is not directly linked with abnormal glucose homeostasis 121 .
Isoform specificity Studies in humans, mice, and cell culture indicate that individual isoforms of the proteins involved in insulin signalling -and termination of insulin signalling -function distinctly. These findings support a combinatorial model of insulin signalling, whereby a single hormone can lead to a remarkable spectrum of consequences. This model has been previously reviewed 10 , and here, we highlight new findings.
IR.
The IR itself has two isoforms, A and B. The latter is generated by alternative splicing and contains an additional exon encoding 11 amino acids 122 . IR-A is notable because it has comparable affinities for insulin and IGF-II. There appear to be small differences in the signalling properties of the two isoforms, such that IR-A is stronger than IR-B in its metabolic effects 123 and in promoting glycogen synthesis 124 . In our view, IR-A functions primarily as a growth-promoting isoform during foetal life, whereas the apparent lower potency of IR-B, the predominant isoform in adult liver 125 , is intended to reduce hepatocyte sensitivity to insulin, in view of the fact that liver cells are exposed to the high insulin concentrations of the portal vein.
IRS.
There are four isoforms of IRS in mammals, although humans lack IRS3 (REF. 126 ). The isoforms differ with respect to tissue distribution and ability to engage a diverse subset of cellular substrates. Thus, the pleiotropy of insulin action can be explained by the ability of these adaptors to engage different cellular pathways. IRS1 and IRS2 are the main isoforms involved in metabolic homeostasis 18 . In the liver, ablation of IRS1 and IRS2 (REFS 127, 128) phenocopies IR knockout, provid ing evidence that they are the main transducers of the insulin signal 129 . Likewise, IRS1 and IRS2 double knockout in muscle impairs cellular metabolism as well as muscle growth 130 , similar to double knockouts of IR and IFG1R in muscle 131 . In contrast to the overlapping cellular functions of IRS1 and IRS2, there are differences in their in vivo functions. Generalized ablation of IRS1 results in growth retardation and skeletal muscle insulin resistance, whereas IRS2 knockouts have strain-specific β-cell failure 10 .
Post-absorptive state
The state following food absorption by the gut, hence the fasting state.
Intensive investigation of the differences in the functions of these two IRS isoforms in the liver has been carried out over the past decade. Hepatocyte-specific knockout of either IRS1 or IRS2 caused moderate defects in glucose metabolism, with some evidence suggesting IRS1 is slightly more valuable for maintaining hepatic metabolism 127, 128, 132, 133 . There may also be temporal (fasting versus postprandial) 128 or spatial (pericentral versus periportal) 134 elements that lend specificity to IRS pathways, and those will be discussed in depth below.
AKT. There are three isoforms of AKT (1-3), and each may have some distinct effects [135] [136] [137] [138] . Although the two major forms of AKT (1 and 2) are not redundant in vivo -as shown by the relevant knockouts -in cells that express both, there appear to be two factors determining the specificity of insulin signalling: their relative abundance as well as their intracellular localization. A body of evidence has suggested that AKT2 is the most important isoform for glucose homeostasis, whereas AKT1 is important for growth and AKT3 for brain development 137 . Indeed, mice lacking Akt2 display impaired glucose homeostasis, while those lacking Akt1 or Akt3 do not 137 . This was supported by in vitro evidence demonstrating a specific mechanism whereby AKT2 is specifically capable of promoting GLUT4 translocation, because it is enriched at the plasma membrane in response to insulin, an effect that is not seen for AKT1 (REFS 139, 140) . These findings emphasized the importance of the subcellular localization of insulin signalling components, and in-depth discussion about the spatial organization is provided below. However, advancements in research tools have allowed a reappraisal of the selectivity of AKT2 in glucose metabolism 141 . New data demonstrate that GLUT4 translocation is maintained after selective, acute inhibition of the kinase activity of either AKT1 or AKT2 (REF. 142 ). This suggests that either isoform is suffic ient and that prior results were due to effects of long-term AKT2 depletion, independent of catalytic activity. On the other hand, there was a speci fic requirement for AKT1 in adipogenesis 142 , thus confirming that isoform specificity is important for some AKT functions.
Temporal regulation
Individual cellular effects of insulin occur with distinct temporal dynamics. These different dynamics depend on the kinetics of insulin secretion, the dynamic expression of insulin signalling proteins, the kinetics of kinase activities downstream of IR and the sensitivity of transcriptional mediators to insulin signalling. Therefore, different biological effects of IR signalling occur at different times after initiation of insulin signalling.
Dynamics of insulin secretion. Although the pattern of insulin secretion falls outside the scope of this review, IR signalling cannot be properly understood without considering that different biological responses by different insulin target cells are also the result of how insulin is released into the bloodstream 143 . In the postabsorptive state, insulin is released -like most hormones -in pulses 144 . In this state, insulin is important for maintaining active protein synthesis, preventing protein degradation and suppressing free fatty acid secretion, which might adversely affect hepatic glucose production 145 . In anticipation of (cephalic phase) and in response to a meal, insulin is secreted in characteristic multi-phasic patterns. Glucose uptake in muscle and fat is likely the earliest response to a rise in plasma insulin, followed by suppression of hepatic glucose production and stimulation of lipogenesis. These dynamics become profoundly altered in insulin resistance and diabetes.
Abundance of insulin signalling proteins. Insulin exerts homeostatic control over its own signalling pathway, turning it down when it is less needed (fasting), and amplifying it in response to nutrient influx. The IRS proteins provide an example. While IRS1 is expressed at a relatively consistent level, IRS2 is most abundant during fasting -because of transcriptional activation by FOXOs -and its levels are decreased by insulin [146] [147] [148] . The importance of this in vivo was highlighted by studies showing that IRS2 carries out insulin signalling mainly during fasting and immediately after feeding, whereas IRS1 does so mainly in the fed state 128 . Similarly, fasting induces FOXO expression in the liver, contributing to the termination of insulin action, while it decreases expression of the sterol regulatory element binding protein 1c (SREBP1c), resulting in inhibition of lipid synthesis. (FIG. 4) . The tem poral dynamics of these sequences lends precision to phosphorylation-dependent protein interactions 149 . Thus, the signalling to entire networks downstream of insulin is conceivably determined by the timing of such phosphorylation events 150 . Phosphoproteomic analyses have demonstrated tyrosine phosphorylation of dozens of proteins in response to insulin [151] [152] [153] [154] . As expected, tyrosine phosphoryl ation of IR and IRS proteins occurs within 1 minute of insulin treatment. Other downstream targets cluster into subcategories in which tyrosine phosphorylation is delayed, even by up to 45 minutes. Likewise, many sites remain 
Phosphorylation in response to insulin. The sequential phosphorylation of downstream targets is a cornerstone of insulin signalling

Exocyst
An octamer assembled to promote intracellular vesicle transport.
COPII complex
A complex of proteins assembled around coat protein II (COPII), required for anterograde transport from the endoplasmic reticulum to the Golgi.
phosphorylated over long periods, whereas others are transient. IRS1 provides an interesting example, as it has multiple phosphotyrosine sites, which display a range of different temporal patterns 153, 154 . Furthermore, there appear to be cell type-specific differences in the timing of IRS1 tyrosine phosphorylation [151] [152] [153] [154] . In contrast to phosphotyrosine sites, the vast majority of insulin-regulated phosphorylation events are on serine residues. In 3T3-L1 adipocytes, the percentages have been quantified as 87.8% phosphoserine, 11.4% phosphothreonine and 0.8% phosphotyrosine 153 . The serine and threonine sites regulated by insulin number in the thousands, and they can be sub divided into multi ple clusters based on shared kinetics. For example, phosphoryl ation of Akt Thr308 occurs within 15 seconds and stabilizes, whereas that of Ser473 follows, peaking after one or more minutes 153, 154 . These specific temporal patterns of phosphorylation may underlie the differential responsiveness of each insulin signalling pathway.
Glucose uptake. The stimulation of cellular glucose uptake was one of the first recognized biological activities of insulin (FIG. 5a) . Although insulin stimulates glucose uptake into many cell types, it has most pronounced effects on adipocytes and muscle cells, enhancing glucose uptake by approximately tenfold and fivefold, respectively 155 . The phenomenon was first described in detail in studies of primary rat adipocytes. Insulin stimu lated glucose uptake, reaching a plateau approx imately ten times higher than that of unstimulated levels, within 15 minutes 156, 157 . The increased rate of glucose uptake was maintained with the continued presence of insulin, and it rapidly returned to pre-stimulated levels once insulin was removed. Cells responded similarly to a second challenge of insulin. Once the glucose transporters had been identified, it could be shown that insulin controls glucose uptake by controlling the density of glucose transporters in the plasma membrane rather than by gating the transporters' activity 158, 159 . Adipocytes and myotubes express GLUT4, a member of the GLUT family of facili tative glucose transporters, and regulation of GLUT4 trafficking to and from the plasma membrane underlies insulin regulation of glucose uptake into these cells.
Insulin signal transduction intersects GLUT4 traffick ing at a number of steps, including the biogenesis of vesicles that ferry GLUT4 to the plasma membrane, docking and fusion with the plasma membrane 160, 161 . These steps occur downstream of AKT activation. However, different effectors control different aspects of GLUT4 trafficking. The best described AKT substrate required for GLUT4 translocation is TBC1 domain family member 4 (TBC1D4; also known as AS160), a RABGAP 162, 163 . AKT phosphorylation of TBC1D4 functionally inactivates its GTPase-activating protein (GAP) activity, resulting in the activation of RAB proteins targeted by TBC1D4 (REFS 161, 164, 165) (FIG. 5b) . In muscle cells, the primary isoform is RAB8a 166 . In fat cells, it is RAB10, which is responsible for about half of the effect of insulin on GLUT4 (REFS 167,168) . RAB10 functions at a step before vesicle docking, and recent evidence suggests it is involved in the biogenesis of GLUT4-containing transport vesicles 169 . Thus, insulin signalling to GLUT4 that is independent of TBC1D4-RAB10 likely targets vesicle docking and fusion. Those effectors are yet to be discovered. Recently, a role for TBK1 kinase regulation of the exocyst in the docking and/or fusion of GLUT4-containing vesicle with the plasma membrane has been reported 170 .
Transcriptional effects of insulin. The effects of insulin are mediated by several transcription factors, including FOXO, SREBP1c, CREB-regulated transcription co-activator 2 (CRTC2) and CREB binding protein (CBP)/p300-interacting transactivator 2 (CITED2). In vivo, evidence for a role of FOXO and SREBP1c is compelling. During fasting, hepatic FOXOs promote the expression of glucose-6-phosphatase and suppress that of gluco kinase, thereby promoting net glucose output [171] [172] [173] [174] . Inactivation of FOXOs by insulin reverses these effects (FIG. 5c) . In addition, FOXOs mediate the effects of insulin on adipocyte differentiation, neuropeptide transcription and processing, and β-cell health [175] [176] [177] [178] [179] . SREBP1c promotes expression of the enzymes involved in fatty acid synthesis 180, 181 . Unlike FOXO, SREBP1c is activated by insulin both transcriptionally and posttranslationally, wherein SREBP1c is processed to its mature form and translocates to the nucleus [182] [183] [184] [185] (FIG. 5c) . The pathways of insulin signalling that regulate FOXOs and SREBP1c diverge, such that SREBP1c regulation is downstream of mTOR 186 , whereas FOXOs are direct targets of AKT [187] [188] [189] . There are also substantial temporal differences in the effects of insulin on FOXO compared with those on SREBP1c. FOXOs are exquisitely and immediately sensitive to insulin, reaching maximal phosphorylation in the liver within 30 seconds of insulin administration in vivo and within 1 minute of insulin treatment in 3T3-L1 adipocytes in vitro 153, 154 . In fact, the peak of FOXO phosphorylation precedes peak activation of AKT 154 . Consequently, the effects of inactivating FOXO to reduce glucose-6-phosphatase and increase gluco kinase occur rapidly 174 . Conversely, SREBP1c activ ation occurs later and requires higher insulin doses. The increases in SREBP1c mRNA and in the mature form of SREBP1c protein peak approximately 12 hours after feeding 190, 191 . Accordingly, the transcriptional targets of SREBP1c also increase several hours after feeding 174, 192, 193 . The slow increase in SREBP1c levels is consistent with SREBP1c maturation being downstream of mTOR 182 , one of the slower targets of insulin to be activated (minutes) 153 . Though considering that SREBP1c is slower yet (hours), the molecular links between mTOR and SREBP1c may lend additional temporal control. One such link is the phosphatidic acid phosphatase lipin 1, which reduces nuclear SREBP1c 194 . mTORC1 phosphorylates lipin 1, leading to the nuclear exclusion of lipin 1 and the accumu lation of nuclear SREBP1c (FIG. 5c) . A second link is CRTC2, which competes with SREBP1c for binding to SEC31A, a compo nent of the COPII complex 195 . Phosphorylation of Nuclear lipin 1 causes nuclear remodelling that reduces nuclear SREBP1c; AKT phosphorylates and inhibits lipin 1. SEC31A is a vesicle transport protein that interacts with the transcription factor CREB-regulated co-activator 2 (CRTC2). After mTOR phosphorylates CRTC2, SEC31A becomes available to instead bind and transport SREBP1c to the nucleus. d | Lysosomal regulation of protein synthesis and degradation. TSC2 promotes the inactive, GDP-bound form of the lysosomally localized protein RHEB. AKT phosphorylates tuberous sclerosis 2 (TSC2), causing its dissociation from the lysosome, thus allowing RHEB to activate its target, mTORC1. e | Tissue microenvironment and cell-cell interactions. Endothelial cells influence parenchymal cell insulin signalling by physically delivering insulin through transcytosis and by suppressing the production of detrimental nitric oxide (NO). Insulin receptor substrate 1 (IRS1) is preferentially expressed in pericentral hepatic cells, as indicated in bold. Notch receptor is activated by a ligand expressed in an adjacent cell. It affects insulin signalling, as its target transcription factor recombining binding protein suppressor of hairless κ (RBPJκ) interacts with FOXO proteins at gene promoters. IRAP, insulin-regulated aminopeptidase.
CRTC2 by mTOR causes it to dissociate from Sec31A, thus enabling the trafficking and activation of SREBP1c (FIG. 5c) . Thus, in addition to the bifurcation of insulin signalling to these two transcription factors, the temporal regulation of these two pathways plays a crucial role in insulin action.
Subcellular spatial regulation
Components of the IR pathway must colocalize in order to transmit downstream signalling. Archetypical examples of this are the recruitment of IRS, PI3K, PDK1, AKT and their cognate phosphatases to the plasma membrane for activation and inactivation, respectively. However, downstream of AKT, there are multiple subcellular sites at which IR signalling targets localize (FIG. 5) .
Trafficking vesicles. After ligand binding, IR is internalized via clathrin-coated vesicles. From their location in endosomes, the IR kinase remains active for signalling, and downstream targets have been found to colocalize to these early endosomes 196, 197 . Evidence suggests that endosomal IR signalling is important for mitogenic but not for metabolic effects of IR 196 . However, because insulin is a weak mitogen, the extent to which the mitogenic effects are the result of IR signalling as opposed to IGF1 receptor signalling remains conjectural 198 . However, a second aspect of IR trafficking in vesicles that can affect metabolic signalling is the fate of the IR for recycling versus degradation. Recently, it was shown that the protein SORLA (sorting-related receptor with type A repeats, encoded by SORL1) directs the recycling of internalized IR back to the cell surface, thereby enhancing IR signalling 199 . This may provide a molecular mechanism for the association of SNPs near SORL1 with obesity traits 200, 201 . A canonical target of insulin signalling that requires spatial regulation in trafficking vesicles is GLUT4. In unstimulated cells, GLUT4 is sequestered intracellularly. Insulin signalling induces its redistribution to the plasma membrane, increasing glucose uptake 158, 159 . Upon cessation of signalling, GLUT4 is retrieved from the plasma membrane, returning to the intracellular storage sites, poised to be re-recruited to the plasma membrane by another round of insulin signalling 157, 158 ( FIG. 5b) . Thus, the control of glucose flux, in both unstimulated and insulin-stimulated fat and muscle cells, requires the activities of a large number of proteins that make the GLUT4 transport vesicles and regulate the fusion of the vesicles with the plasma membrane. This is one of the best characterized examples of regulation of biological activity by controlled compartmentalization.
Insulin stimulation of glucose uptake is most pronoun ced in fat and muscle cells, although insulin promotes a small (less than twofold) uptake into many cell types. This specialization is fat and muscle cell dependent. Ectopic expression of GLUT4 in other cell types does not by itself recapitulate its insulin-dependent trans location to the plasma membrane characteristic of fat and muscle cells 202 . Insulin does not modify GLUT4 directly; instead, it acts on the trafficking pathway that transports GLUT4 to the plasma membrane.
The insulin-regulated aminopeptidase (IRAP) is also trans located to the plasma membrane, with GLUT4 (REF. 203 ). IRAP is a component of vesicles that ferry GLUT4 to the plasma membrane, but it does not have a major role in glucose homeostasis 204 . Moreover, GLUT4-containing vesicles have not been reported to contain soluble proteins that are secreted concurrent with GLUT4 insertion into the membrane, suggesting that insulin-regulated trafficking of membrane proteins is restricted to a remodelling of the plasma membrane rather than being coupled to adipokine secretion. Overall, insulin control of GLUT4 translocation is a prime example of the regulation of insulin effects through compartmentalization, as well as of tyrosine kinase-dependent regulation of membrane trafficking.
Nuclear actions of insulin. The discovery that insulin causes the AKT-dependent nuclear exclusion of FOXOs shifted the focus on insulin signalling from the membrane to the nucleus. This mechanism is neither unique to FOXO nor unidirectional. The insulin-stimulated translocation of mature SREBP1c to the nucleus is one example. Another is the CREB co-activator CRTC2, which is phosphorylated by SIK2, an AKT substrate, and excluded from the nucleus 205, 206 (FIG. 5c) .
FOXO subcellular localization is regulated by other signalling pathways that either function in conjunction with insulin to promote the nuclear exclusion of FOXOs, or counteract it. Fasting and glucagon 207 , cytokine-and other stress-activated pathways 208, 209 promote the import of FOXOS into the nucleus from the cytoplasm. Moreover, other nutritional cues can complement -or compete with -insulin and glucagon to influence FOXO localiza tion through mechanisms other than phosphorylation. Oxidative stress causes FOXO deacetylation, which promotes nuclear retention and activation of FOXOs but also promotes rapid ubiquitylation and degradation 179, 210 . On the other hand, acetylation sensitizes FOXOs to insulin-induced phosphorylation while increasing stability 179, 211 . These modifications influence FOXO activity in multiple cell types including β-cells, hepatocytes, macrophages and endothelial cells 179, [212] [213] [214] .
Lysosome. The lysosome, where mTORC1 is activated 215 , has emerged as an important site of cellular insulin signal ling (FIG. 5d) . mTORC1 translocates to the lysosome in response to amino acids, a process that is mediated by a protein complex termed the Ragulator 216 . At the lysosomal membrane, mTORC1 interacts with its activator, RHEB. However, mTORC1 activation by RHEB only proceeds if insulin signalling is also activated. This is because in the absence of insulin signalling, RHEB is kept in its GDP-bound, inactive state by the GTPase-activating TSC protein complex 217 . Following insulin stimulation, AKT phosphorylates and inactivates TSC2 (REFS 218, 219) . Recent work demonstrates that AKT-mediated phosphorylation causes TSC2 to dissoci ate from the lysosome 220 . This stabilizes the GTPbound, active form of RHEB, thus activating mTORC1. These findings demonstrate spatial coordination
Transcytocis
The transport of proteins across the interior of a cell.
of multiple signalling proteins at the lysosome as a mechanism to tightly control mTORC1 activation in response to both hormonal (insulin) and nutritional (amino acid) cues.
Regulation at endoplasmic reticulum-mitochondria contact sites. Mitochondria-associated endoplasmic reticulum membranes (MAMs) are endoplasmic reticulum membrane subdomains that interact physically with mitochondria. This juxtaposition facilitates the transfer of calcium and lipids between the two organelles and is thus considered a site where signalling pathways -particu larly those relying on calcium flux -intersect with energy and lipid metabolism pathways 221 . Recent evidence suggests that MAMs are an important target site for insulin signalling 222 . AKT and mTORC2 -the kinase complex that is responsible for carrying out the Ser473 phosphorylation of AKT -are localized to MAMs, and this localization is increased with insulin signalling [223] [224] [225] [226] . Evidence suggests that the localization of mTORC2 and of AKT-pS473 to MAMs contributes to the regulation of MAM function and calcium flux 224 . Conversely, the integrity of the MAMs contrib utes to insulin signalling, as disruption of MAMs dampens insulin signalling and impairs glucose homeostasis 225, 227 . Moreover, overabundance of MAMs worsens insulin signalling and glucose metabolism 228 . These findings indicate that the formation and number of MAMs both affect and are affected by insulin signalling in multiple ways.
Tissue microenvironment
In addition to the subcellular organization of IR targets, the spatial distribution of cells within a tissue can also impact insulin signalling (FIG. 5e) . There are many neuronal, hormonal and metabolic signals that link distant tissues and affect insulin signalling, which are outside the scope of this review. Instead, this section will focus on the local effects of neighbouring cells within the same tissue. A seminal demonstration that neighbouring cells can affect insulin signalling is provided by the infiltration of macrophages into the adipose tissue during obesity, which can initiate inflammatory pathways that impair insulin signalling [30] [31] [32] . Other cell-cell interactions that affect insulin signalling occur between the same or different cell types. This section highlights that insulin action in a given cell can be influenced by its spatial position ing in a tissue, via paracrine effects or differences in nutrient and/or hormone access.
Hepatic zonation. Hepatocytes are arranged in zones, described by their proximity to the portal vein (rich with nutrients and oxygen) or the central vein (relatively deprived of nutrients and oxygen). It has long been known that certain metabolic pathways are preferentially localized to different zones, and interconnected pathways are localized together. Fatty acid oxidation and gluconeogenesis are localized to periportal hepatocytes, whereas glycolysis and fatty acid synthesis are localized to pericentral hepatocytes 229 . Recently, it was reported that while IR, IRS2 and AKT are equally distributed, IRS1 is twice as abundant in pericentral hepatocytes as in periportal hepatocytes 134 . This may cause IRS1 to be preferentially involved in glycolytic and lipogenic pathways, potentially providing another layer of specificity for coordinated regulation of metabolic pathways.
Endothelial-parenchymal cell interactions.
A neighbouring non-parenchymal cell type that can impact parenchymal cell insulin signalling is endothelial cells. One potential mechanism for this lies in their role in delivering insulin from plasma into the interstitium. This can occur through regulation of blood flow and through the transcytosis of insulin across the endothelium 230, 231 . The latter is thought to be rate-limiting for insulin delivery into tissues such as muscle and adipose tissue, where capillaries are lined with continuous endothelial cells 230 . However, the mechanisms of insulin delivery remain unclear. In vitro evidence suggests that the transcytosis is mediated by IR in endothelial cells 232, 233 . However, mice lacking IR specifically in endothelial cells maintain normal insulin sensitivity unless placed on a low-salt diet 234 . This finding is unexpected, but may be explained by the preservation of IGF1R in these mice. On the other hand, mice lacking IRS2 -or both IRS1 and IRS2 -in endothelial cells are insulin resistant, with impaired muscle glucose uptake 235 . This is due to poor insulinstimulated capillary recruitment and insulin delivery to the interstitium, resulting in reduced AKT activation.
A second potential mechanism involves paracrine factors secreted from the endothelial cells that affect insulin signalling in parenchymal cells. Mice lacking FOXOs in endothelial cells display insulin resistance and impaired insulin signalling in hepatocytes 236 . This is associated with excessive release of nitric oxide from liver sinusoidal endothelial cells and concomitant tyrosine nitration of IR in hepatocytes. This highlights how insulin signalling in one cell type can influence insulin signalling in an adjacent cell type.
Other cell-cell interactions. Additional cell-cell interactions in the tissue microenvironment may also impact insulin signalling. One example is the unexpected finding that NOTCH receptors -best known for their role in development -are negative regulators of insulin signalling in mature cells 237, 238 . Notch receptors on the surface of a cell are activated by the binding of transmembrane protein ligands that are expressed on the surface of an adjacent cell 239 . This causes the intracellular domain of NOTCH to become cleaved and transported to the nucleus where it binds to the transcription factor recombining binding protein suppressor of hairless κ (RBPJκ) and regulates gene expression. Mice that are heterozygous for NOTCH, or that lack RBPJκ specifically in hepatocytes, have enhanced insulin signalling in liver including elevated AKT phosphorylation and improved suppression of hepatic glucose production 237 . This pathway is confirmed to be downstream of signalling from an adjacent cell, as expressing only the extracellular domain of NOTCH -which sequesters endogenous ligands on adjacent cells -is sufficient to invoke the pathway and enhance AKT phosphorylation at Thr308 (REF. 238 ).
Conclusions and perspectives
As we approach the 100th anniversary of the discovery of insulin, the signalling pathways of this important hormone have largely been defined. Although there will always be gaps in our understanding, progress has been substantial. However, we should acknowledge the limits of a reductionist cellular and biochemical approach to insulin signalling. In the living organism, the integrated signals arising from insulin's pleiotropic actions in multiple tissues cannot be easily reconciled with intrinsic cellular pathways -to wit, the complexity of distinguishing between direct effects of insulin in the liver from indirect effects caused by substrate redistribution in other organs 171, 240 . A second conclusion relates to the clinical implications of these discoveries. The heterogeneity of insulin signalling has thus far defeated approaches to discover clinically useful insulin sensitizers: turning on the main path through IR, IRS, PI3K, AKT is fraught with risks, while turning off antagonistic signals, such as FOXO or the many serine/ threonine kinase or phosphatases, appears unlikely to succeed in view of the built-in redundancy of these systems. Nonetheless, the body of knowledge developed in this field will prob ably contribute to the solution of the clinical problem of insulin resistance in its various clinical manifestations.
